Stockreport

Hemophilia B Drug Market Size and Share to Grow by 2032, Assesses DelveInsight | Key Emerging Therapies - CSL222, SerpinPC, AskBio009, PF-06838435/fida, Marstacimab, FLT180a, Concizumab, F...

CSL LTD SP/ADR  (CSLLY) 
NASDAQ:AMEX Investor Relations: csl.com/investors
PDF The major reason behind the hemophilia B market upsurge is the launch of the most anticipated gene therapies by key companies such as CSL Behring, ApcinteX Ltd, Centessa [Read more]